Ovarian Cancer

Patients with ovarian cancer tend to underreport their most challenging symptoms; however, an analysis of their online comments could give health care providers insight into how to help.

Despite increased physical activity, nutritional intake behavior among female cancer survivors did not improve with an exercise intervention program, according to a randomized-controlled trial.

An expert discusses the exciting new developments extending survival in the evolving ovarian cancer treatment space.

A young advocate emphasizes the importance of communication between parents and their children about an ovarian cancer diagnosis.

A gynecologic-oncology clinical nurse specialist and one of this year’s CURE Ovarian Cancer Heroes discussed the lack of resources for patients with ovarian cancer and the need for more research.

We've got a sneak peek at what’s inside CURE®'s Women’s Cancers issue.

Patients speak up on the rarely discussed side effects of gynecologic cancers.

Women with this disease are living longer, despite common recurrence.

An endometrial cancer survivor runs to raise awareness for a disease many don’t want to talk about.

Cancer isn’t black and white, nor is it predictable. A diagnosis and the subsequent treatment of the many varieties of this complex disease can be challenging because of gray areas and uncertainties.

The “Whiskey Cavalier” actor opens up about caregiving for his mother following her ovarian cancer diagnosis.

This week, we spoke with all three of CURE’s 2019 Ovarian Cancer Heroes: Ryan Mitstifer Walton, Paula Anastasia, RN, MN, AOCN, and Shannon Westin, M.D., M.P.H.

Researchers define the genetic characteristics of ovarian tumors-- information that could lead to new opportunities for personalized therapy and may explain why screening programs for the disease haven’t been successful.

Ten years later, a woman with a BRCA1 mutation finally feels more like herself.

Understand how the rare relative of ovarian cancer is diagnosed and treated.

Did we bring this scary, painful, financially draining monster into our lives by eating too many cookies and not doing enough jumping jacks? We need a reliable diagnostic screening tool for ovarian cancer and we need it now.

In this week’s episode, we spoke with the most decorated Olympic gymnast and ovarian cancer survivor Shannon Miller before CURE’s second annual Ovarian Cancer Heroes gala.

Lenvima (lenvatinib) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, according to results from a phase I study.

Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.

The importance of teamwork between patients and their caregivers was a common theme at the second annual Ovarian Cancer Heroes event held in Honolulu, Hawaii.

In this week’s episode, we spoke with actor Scott Foley, who opened up about his experience as a caregiver to his mother after her ovarian cancer diagnosis and why he joined the Not on My Watch movement to help educate others.

From shark genomes to celebs and important updates, here is a quick overview of what is making headlines in the cancer space.

“Love, Gilda” fea­tures never-before-seen diaries, audio and videotapes from the collection of Gilda Radner, who died at age 42 of ovarian cancer.

This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.

Researchers are evaluating the use of folate receptors to treat platinum-resistant ovarian cancer.

Nearly 90 percent of women experienced sexual dysfunction; however, providers were not openly communicating about this side effect, according to survey results.

There is a flood of information available about genetic tests for cancer risk in the media, and even at community events, such as health fairs and senior centers. If these promotions have caught your attention and you are considering testing, there is important information that you should know first.